董事介绍
注：董事持股数取自最新公司公告
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 常东亮 | 男 | Founder and Chairman of Board | 45 | 未披露 | 5481.97 | 2021-05-17 |
| Steven Foo | 男 | Chief Financial Officer, Chief Executive Officer | 48 | 未披露 | 123.77 | 2021-05-17 |
董事简历
中英对照 | 中文 | 英文- 常东亮
-
常东亮，创始人&CEO。理工生物技术博士，浙江省151人才第一梯队浙江省专家。2013年创建摩贝信息技术，十多年的生物医药行业的技术和管理经验，获2015年度中国B2B行业最佳新锐CEO。嘉兴应用化学工程中心主任；中化广东有机化学品事业部经理；先后创立中科化学、中科检测等公司。
Dongliang Chang is our founder and has served as the chairman of our board of directors since our inception. Dr. Chang is a renowned expert in biochemistry and has been instrumental to the growth and success of our Company. His research focuses on organic synthesis, bio-informatics, heterocyclic intermediates, bio-catalysis and published more than 30 articles at reputable publishers, including, among others, Biocatalysis and Biotransformation, The Journal of Organic Chemistry and Chemical Communications, and received 11 patents. Dr. Chang received his doctorate degree from Swiss Federal Institute of Technology in biotechnology in 2004. - 常东亮，创始人&CEO。理工生物技术博士，浙江省151人才第一梯队浙江省专家。2013年创建摩贝信息技术，十多年的生物医药行业的技术和管理经验，获2015年度中国B2B行业最佳新锐CEO。嘉兴应用化学工程中心主任；中化广东有机化学品事业部经理；先后创立中科化学、中科检测等公司。
- Dongliang Chang is our founder and has served as the chairman of our board of directors since our inception. Dr. Chang is a renowned expert in biochemistry and has been instrumental to the growth and success of our Company. His research focuses on organic synthesis, bio-informatics, heterocyclic intermediates, bio-catalysis and published more than 30 articles at reputable publishers, including, among others, Biocatalysis and Biotransformation, The Journal of Organic Chemistry and Chemical Communications, and received 11 patents. Dr. Chang received his doctorate degree from Swiss Federal Institute of Technology in biotechnology in 2004.
- Dawei Ma
-
Dawei Ma于2019年12月27日开始担任我们的独立董事。他目前是上海有机化学研究所的副所长和《有机化学杂志》的副主编。在此之前，他于2001年至2010年担任上海有机化学研究所生物有机和天然产物化学国家重点实验室主任。他自1995年以来被任命为上海有机化学研究所的研究教授。他于1984年在山东大学获得化学学士学位，并于1989年在上海有机化学研究所获得博士学位，并且是匹兹堡大学梅奥诊所的博士后学者。
Dawei Ma started to serve as our independent director since December 2019. Dr. Ma is currently research professor of Shanghai Institute of Organic Chemistry and an associate editor of Journal of Organic Chemistry. He also holds the board chairman position of Zhejiang CE Pharm, a start-up company to develop new technologies for manufacturing drug intermediates. Prior to that, Dr. Ma served as the director of the State Key Laboratory of Bioorganic and Natural Products Chemistry of Shanghai Institute of Organic Chemistry from 2001 to 2010. Dr. Ma has been appointed as research professor at Shanghai Institute of Organic Chemistry since 1995. Dr. Ma received his bachelor's degree in chemistry from Shandong University in 1984 and doctorate degree from Shanghai Institute of Organic Chemistry in 1989 and was a postdoctoral scholar at Mayo Clinic of University of Pittsburgh. - Dawei Ma于2019年12月27日开始担任我们的独立董事。他目前是上海有机化学研究所的副所长和《有机化学杂志》的副主编。在此之前，他于2001年至2010年担任上海有机化学研究所生物有机和天然产物化学国家重点实验室主任。他自1995年以来被任命为上海有机化学研究所的研究教授。他于1984年在山东大学获得化学学士学位，并于1989年在上海有机化学研究所获得博士学位，并且是匹兹堡大学梅奥诊所的博士后学者。
- Dawei Ma started to serve as our independent director since December 2019. Dr. Ma is currently research professor of Shanghai Institute of Organic Chemistry and an associate editor of Journal of Organic Chemistry. He also holds the board chairman position of Zhejiang CE Pharm, a start-up company to develop new technologies for manufacturing drug intermediates. Prior to that, Dr. Ma served as the director of the State Key Laboratory of Bioorganic and Natural Products Chemistry of Shanghai Institute of Organic Chemistry from 2001 to 2010. Dr. Ma has been appointed as research professor at Shanghai Institute of Organic Chemistry since 1995. Dr. Ma received his bachelor's degree in chemistry from Shandong University in 1984 and doctorate degree from Shanghai Institute of Organic Chemistry in 1989 and was a postdoctoral scholar at Mayo Clinic of University of Pittsburgh.
- Ning Zhu
-
Ning Zhu自2019年12月起担任Waterdrop Inc.独立董事。Zhu博士自2010年1月起担任上海交通大学上海高级金融学院的金融学教授和副院长。在此之前，2003年至2010年1月，他是加州大学金融学终身教授。Zhu博士也是中国华融资产管理有限公司的独立非执行董事。Zhu博士于1997年获得北京大学国际金融学士学位，1999年获得Cornell大学管理学硕士学位，2003年获得耶鲁大学金融学博士学位。
Ning Zhu,has served as Waterdrop Inc. independent director since May 2022. Mr. Zhu has been a senior partner and Head of China of Brunswick Group since September 2022. He has also been a professor of finance and the deputy dean of Shanghai Advanced Institute of Finance of Shanghai Jiaotong University since July 2010. Prior to that, Mr. Zhu was a tenured professor of finance at University of California (Davis) from 2003 to June 2010. Mr. Zhu is also an independent non-executive director of each of China Huarong Asset Management Co., Ltd. (HKEX: 2799) and CHINA BOHAI BANK CO., LTD. (HKEX: 9668), and an independent director of each of Molecular Data Inc. (Nasdaq: MKD), Jinke Property Group Co., Ltd. (SZSE: 000656) and China CITIC Bank International Limited. Mr. Zhu received his bachelor's degree in international finance from Peking University in 1997, master's degree in management from Cornell University in 1999, and doctorate degree in finance from Yale University in 2003. - Ning Zhu自2019年12月起担任Waterdrop Inc.独立董事。Zhu博士自2010年1月起担任上海交通大学上海高级金融学院的金融学教授和副院长。在此之前，2003年至2010年1月，他是加州大学金融学终身教授。Zhu博士也是中国华融资产管理有限公司的独立非执行董事。Zhu博士于1997年获得北京大学国际金融学士学位，1999年获得Cornell大学管理学硕士学位，2003年获得耶鲁大学金融学博士学位。
- Ning Zhu,has served as Waterdrop Inc. independent director since May 2022. Mr. Zhu has been a senior partner and Head of China of Brunswick Group since September 2022. He has also been a professor of finance and the deputy dean of Shanghai Advanced Institute of Finance of Shanghai Jiaotong University since July 2010. Prior to that, Mr. Zhu was a tenured professor of finance at University of California (Davis) from 2003 to June 2010. Mr. Zhu is also an independent non-executive director of each of China Huarong Asset Management Co., Ltd. (HKEX: 2799) and CHINA BOHAI BANK CO., LTD. (HKEX: 9668), and an independent director of each of Molecular Data Inc. (Nasdaq: MKD), Jinke Property Group Co., Ltd. (SZSE: 000656) and China CITIC Bank International Limited. Mr. Zhu received his bachelor's degree in international finance from Peking University in 1997, master's degree in management from Cornell University in 1999, and doctorate degree in finance from Yale University in 2003.
高管简历
中英对照 | 中文 | 英文- 常东亮
常东亮，创始人&CEO。理工生物技术博士，浙江省151人才第一梯队浙江省专家。2013年创建摩贝信息技术，十多年的生物医药行业的技术和管理经验，获2015年度中国B2B行业最佳新锐CEO。嘉兴应用化学工程中心主任；中化广东有机化学品事业部经理；先后创立中科化学、中科检测等公司。
Dongliang Chang is our founder and has served as the chairman of our board of directors since our inception. Dr. Chang is a renowned expert in biochemistry and has been instrumental to the growth and success of our Company. His research focuses on organic synthesis, bio-informatics, heterocyclic intermediates, bio-catalysis and published more than 30 articles at reputable publishers, including, among others, Biocatalysis and Biotransformation, The Journal of Organic Chemistry and Chemical Communications, and received 11 patents. Dr. Chang received his doctorate degree from Swiss Federal Institute of Technology in biotechnology in 2004.- 常东亮，创始人&CEO。理工生物技术博士，浙江省151人才第一梯队浙江省专家。2013年创建摩贝信息技术，十多年的生物医药行业的技术和管理经验，获2015年度中国B2B行业最佳新锐CEO。嘉兴应用化学工程中心主任；中化广东有机化学品事业部经理；先后创立中科化学、中科检测等公司。
- Dongliang Chang is our founder and has served as the chairman of our board of directors since our inception. Dr. Chang is a renowned expert in biochemistry and has been instrumental to the growth and success of our Company. His research focuses on organic synthesis, bio-informatics, heterocyclic intermediates, bio-catalysis and published more than 30 articles at reputable publishers, including, among others, Biocatalysis and Biotransformation, The Journal of Organic Chemistry and Chemical Communications, and received 11 patents. Dr. Chang received his doctorate degree from Swiss Federal Institute of Technology in biotechnology in 2004.
- Steven Foo
Steven Foo自2019年4月以来一直担任我们的首席财务官。之前，Foo先生曾担任Hebron Technology的董事会成员兼首席财务官。 在此之前，他曾担任Legg Mason资产管理亚洲区首席运营官，曾担任London Asia Capital Plc亚太区首席财务官，曾任德意志银行Alex Brown的投资分析师，并曾担任国际联盟亚太区的总监，其总部位于纽约的私募股权配售代理和跨境战略咨询公司（IAA）。Foo先生为资深特许会计师及注册会计师（CPA）。Foo先生除了具有SEC合规性方面的经验外，还在战略，财务管理和资本市场方面拥有丰富的领导经验。
Steven Foo has served as our chief financial officer since April 2019. Previously, Mr. Foo served as a member of the Board of Directors and Chief Financial Officer of Hebron Technology. Prior to that, he worked as Chief Operating Officer of Legg Mason Asset Management Asia, served as CFO of Asia Pacific for London Asia Capital Plc, was an Investment Analyst at Deutsche Bank Alex Brown, and served as the Director of Asia Pacific for International Alliance Associates (IAA), the New York-based private equity placement agent and cross-border strategic advisory firm. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in SEC compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets.- Steven Foo自2019年4月以来一直担任我们的首席财务官。之前，Foo先生曾担任Hebron Technology的董事会成员兼首席财务官。 在此之前，他曾担任Legg Mason资产管理亚洲区首席运营官，曾担任London Asia Capital Plc亚太区首席财务官，曾任德意志银行Alex Brown的投资分析师，并曾担任国际联盟亚太区的总监，其总部位于纽约的私募股权配售代理和跨境战略咨询公司（IAA）。Foo先生为资深特许会计师及注册会计师（CPA）。Foo先生除了具有SEC合规性方面的经验外，还在战略，财务管理和资本市场方面拥有丰富的领导经验。
- Steven Foo has served as our chief financial officer since April 2019. Previously, Mr. Foo served as a member of the Board of Directors and Chief Financial Officer of Hebron Technology. Prior to that, he worked as Chief Operating Officer of Legg Mason Asset Management Asia, served as CFO of Asia Pacific for London Asia Capital Plc, was an Investment Analyst at Deutsche Bank Alex Brown, and served as the Director of Asia Pacific for International Alliance Associates (IAA), the New York-based private equity placement agent and cross-border strategic advisory firm. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in SEC compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets.